Thus, nanoparticles are expected to serve as an efficient tool to deliver therapeutic agents (including TNF antagonist) or even to directly regulate TNF-TNFR2 interactions in breast cancer cells. The gene discussed is TNFRSF1B; the disease is breast carcinoma.